Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences Expands and Extends Collaboration With Janssen

12/06/2021 | 09:06am EST


ę MT Newswires 2021
All news about KALEIDO BIOSCIENCES, INC.
01/28KALEIDO BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
01/21Kaleido Reports Findings From Study Data of Proposed Inflammatory Bowel Disease Treatme..
MT
01/21Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 ..
GL
01/21Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 ..
GL
2021KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Biotechnology Index
CI
2021Kaleido Biosciences Expands and Extends Collaboration With Janssen
MT
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
GL
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
CI
2021Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
2021Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -0,77x
Yield 2021 -
Capitalization 74,1 M 74,1 M -
EV / Sales 2021 42,5x
EV / Sales 2022 20,1x
Nbr of Employees 82
Free-Float 91,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 1,74 $
Average target price 14,80 $
Spread / Average Target 751%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-27.20%74
MODERNA, INC.-37.21%64 657
LONZA GROUP AG-17.41%50 233
IQVIA HOLDINGS INC.-15.35%45 624
SEAGEN INC.-17.45%23 336
ICON PUBLIC LIMITED COMPANY-15.10%21 404